Chargement en cours...
Initiating oral fingolimod treatment in patients with multiple sclerosis
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding DMT options for patients with MS. In three large...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3707354/ https://ncbi.nlm.nih.gov/pubmed/23858329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285613491520 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|